In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SFDA To Disclose Government Information

This article was originally published in PharmAsia News

Executive Summary

China's State FDA will voluntarily disclose nine categories of government information including: organizational functions, personnel information, regulations and documents, announcements and notices, planning and programs, integration management, basic statistics, administrative permission and latest news. Citizens, legal entities and institutions may request such data from SFDA. Information such as quality bulletins, illegal drug advertisement notices, GMP and GSP authentication, adverse drug effects, tenders, key project approval and other details will be published at its website as well as via news conferences, newspapers, radio and TV to facilitate public access. The agency has officially started accepting such information requests since May 1. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068497

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel